martes, 13 de febrero de 2024

Semaglutide and beyond: a turning point in obesity pharmacotherapy

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(24)00026-7/fulltext?dgcid=hubspot_update_feature_updatealerts_lanepe&utm_campaign=update-lanepe&utm_medium=email&_hsmi=293795093&_hsenc=p2ANqtz-_T_GPj7OHthBdpAzgWwp6F8N7fgLOGZ_d1BV2l1sBNAme3BFhwIjj1w4NMJfF4OVT8exsr17xbjgqC4DpC6QwSWJRz-A&utm_content=293762779&utm_source=hs_email

No hay comentarios: